Provided by Tiger Trade Technology Pte. Ltd.

F/m Emerald Life Sciences Innovation ETF

45.14
-0.9465-2.05%
Post-market: 45.140.00000.00%16:15 EDT
Volume:984
Turnover:44.72K
Market Cap:124.45M
PE:- -
High:45.44
Open:45.44
Low:45.14
Close:46.09
52wk High:48.78
52wk Low:28.78
Shares:2.76M
Float Shares:2.76M
Volume Ratio:0.41
T/O Rate:0.04%
Dividend:- -
Dividend Rate:- -
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Amneal Pharmaceuticals announces FDA approval and launch of Lanreotide

TIPRANKS
·
1 hour ago

Electra Therapeutics indicated to open at $20, IPO priced at $15

TIPRANKS
·
Yesterday

Abeona Therapeutics ‘congratulated’ Ultragenyx on U.S FDA approval of UX111

TIPRANKS
·
Yesterday

Travere Therapeutics SVP, Chief Accounting Officer Sandra Calvin Disposes of $335,983 in Common Shares

Reuters
·
Yesterday

Guardant Health Director Tariq Musa Sells 116 Common Shares for $20,300

Reuters
·
Yesterday

Ultragenyx confirms FDA approval of Fayuvi

TIPRANKS
·
Yesterday

FDA approves Ultragenyx gene therapy for Sanfilippo syndrome type A

TIPRANKS
·
Yesterday

US Health Secretary Kennedy Jr. Adds Eight New Members to Key Health Committee

Reuters
·
Sep 17

Guardant Health on Track for Record High Close

Dow Jones
·
Sep 17

Nuvation Bio announces FDA approval of sNDA for Ibtrozi

TIPRANKS
·
Sep 17

Bayer receives FDA approval for Kerendia for CKD with type 1 diabetes

TIPRANKS
·
Sep 17

Longeveron’s laromestrocel did not meet primary endpoint in Phase 2b HLHS trial

TIPRANKS
·
Sep 17

Guardant Health Could Benefit From AstraZeneca Trial Failure, UBS Says

MT Newswires Live
·
Sep 16

ASX biotech expands diagnostics portfolio after FDA approval

Morning Star AU
·
Sep 16

Cogent Biosciences reports FDA acceptance of bezuclastinib new drug application

TIPRANKS
·
Sep 15

Cogent Biosciences, - FDA States no Advisory Committee Planned and no Review Issues Identified

THOMSON REUTERS
·
Sep 15

Cogent Biosciences Announces FDA Acceptance of New Drug Application (Nda) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (Advsm)

THOMSON REUTERS
·
Sep 15

Cogent Biosciences, - FDA Accepts Nda for Bezuclastinib in Advsm with Pdufa Date June 29, 2027

THOMSON REUTERS
·
Sep 15

Press Release: Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer

Dow Jones
·
Sep 15

Barclays downgrades Scholar Rock on valuation after FDA approval

TIPRANKS
·
Sep 15